Combination chemotherapy with doxorubicin, bleomycin, and vindesine for AIDS-related Kaposi's sarcoma

✍ Scribed by Marcello Tavio; Emanuela Vaccher; Andrea Antinori; Adriana Ammassari; Marco Cusini; Marco Fasan; Vincenzo Accurso; Luigi P. Garavelli; Lazzaro Repetto; Umberto Tirelli

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 550 KB
• Volume: 77
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19960515)77:10<2117::aid-cncr23>3.0.co;2-x

✦ Synopsis

BACKGROUND.

Kaposi's sarcoma is the most common neoplasm in patients with human immunodeficiency virus (IIIV) infection. Although the best therapeutic approach is still unclear, patients with advanced KS are usually treated with systemic chemotherapy.

METHODS.

A prospective multiinstitutional Italian study evaluated the efficacy and toxicity of combination chemotherapy with doxorubicin, bleomycin, and vindesine (ABVi) in patients with progressive and extensive HIV-related KS. Patients were given doxorubicin, 20 mg/mz on Day 1; bleomycin, 15 mg on Day 1, and vindesine, 4 mg on Day 1 hiweekly t granulocyte-colony stimulating factor.